BACKGROUND AND OBJECTIVES: The objective of this study was to describe the renal and extrarenal findings in patients with recessively inherited familial hypomagnesemia with hypercalciuria and nephrocalcinosis (FHHNC) associated with CLDN19 mutations. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Medical records of three patients from two French unrelated families with CLDN19 mutations were retrospectively examined. RESULTS: Direct sequencing of CLDN19 identified a known variant (p.Gly20Asp) in all patients and a new missense mutation (p.Val44Met) in one (compound heterozygous). The patients' renal phenotype closely mimicked CLDN16-related nephropathy: low serum Mg2+ (<0.65 mmol/L) despite oral supplementation, hypercalciuria partly thiazide-sensitive, and progressive renal decline with ESRD reached at age 16 and 22 years in two individuals. Primary characteristics (failure to thrive, recurrent urinary tract infections, or abdominal pain), age at onset (0.8 to 16 years), and rate of renal decline were highly heterogeneous. Ocular involvement was identified in all patients, although two patients did not have visual loss. Additionally, exercise intolerance with pain, weakness, and electromyographical alterations mimicking a Ca2+/K+ channelopathy (pattern V) were observed in two of three individuals. These features persisted despite the normalization of serum K+ and Mg2+ after renal transplantation. CONCLUSIONS: Ocular manifestations, even subtle, and exercise intolerance mimicking mild to moderate periodic paralysis are two symptoms that need to be searched for in patients with FHHNC and may indicate CLDN19 mutations.
BACKGROUND AND OBJECTIVES: The objective of this study was to describe the renal and extrarenal findings in patients with recessively inherited familial hypomagnesemia with hypercalciuria and nephrocalcinosis (FHHNC) associated with CLDN19 mutations. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Medical records of three patients from two French unrelated families with CLDN19 mutations were retrospectively examined. RESULTS: Direct sequencing of CLDN19 identified a known variant (p.Gly20Asp) in all patients and a new missense mutation (p.Val44Met) in one (compound heterozygous). The patients' renal phenotype closely mimicked CLDN16-related nephropathy: low serum Mg2+ (<0.65 mmol/L) despite oral supplementation, hypercalciuria partly thiazide-sensitive, and progressive renal decline with ESRD reached at age 16 and 22 years in two individuals. Primary characteristics (failure to thrive, recurrent urinary tract infections, or abdominal pain), age at onset (0.8 to 16 years), and rate of renal decline were highly heterogeneous. Ocular involvement was identified in all patients, although two patients did not have visual loss. Additionally, exercise intolerance with pain, weakness, and electromyographical alterations mimicking a Ca2+/K+ channelopathy (pattern V) were observed in two of three individuals. These features persisted despite the normalization of serum K+ and Mg2+ after renal transplantation. CONCLUSIONS: Ocular manifestations, even subtle, and exercise intolerance mimicking mild to moderate periodic paralysis are two symptoms that need to be searched for in patients with FHHNC and may indicate CLDN19 mutations.
Authors: Gudmar Thorleifsson; Hilma Holm; Vidar Edvardsson; G Bragi Walters; Unnur Styrkarsdottir; Daniel F Gudbjartsson; Patrick Sulem; Bjarni V Halldorsson; Femmie de Vegt; Frank C H d'Ancona; Martin den Heijer; Leifur Franzson; Claus Christiansen; Peter Alexandersen; Thorunn Rafnar; Kristleifur Kristjansson; Gunnar Sigurdsson; Lambertus A Kiemeney; Magnus Bodvarsson; Olafur S Indridason; Runolfur Palsson; Augustine Kong; Unnur Thorsteinsdottir; Kari Stefansson Journal: Nat Genet Date: 2009-06-28 Impact factor: 38.330
Authors: S Weber; K Hoffmann; N Jeck; K Saar; M Boeswald; E Kuwertz-Broeking; I I Meij; N V Knoers; P Cochat; T Suláková; K E Bonzel; M Soergel; F Manz; K Schaerer; H W Seyberth; A Reis; M Konrad Journal: Eur J Hum Genet Date: 2000-06 Impact factor: 4.246
Authors: Stefanie Weber; Linda Schneider; Melanie Peters; Joachim Misselwitz; Gabriele Rönnefarth; Michael Böswald; Klaus E Bonzel; Tomas Seeman; Tereza Suláková; Eberhard Kuwertz-Bröking; Alojz Gregoric; Jean-Bernard Palcoux; Velibor Tasic; Friedrich Manz; Karl Schärer; Hannsjörg W Seyberth; Martin Konrad Journal: J Am Soc Nephrol Date: 2001-09 Impact factor: 10.121
Authors: T Kuntzer; F Flocard; C Vial; A Kohler; M Magistris; A Labarre-Vila; P M Gonnaud; F Ochsner; P Soichot; V Chan; G Monnier Journal: Muscle Nerve Date: 2000-07 Impact factor: 3.217
Authors: Vidar O Edvardsson; David S Goldfarb; John C Lieske; Lada Beara-Lasic; Franca Anglani; Dawn S Milliner; Runolfur Palsson Journal: Pediatr Nephrol Date: 2013-01-20 Impact factor: 3.714
Authors: Paulo Marcio Yamaguti; Pollyanna Almeida Costa dos Santos; Bruno Sakamoto Leal; Viviane Brandão Bandeira de Mello Santana; Juliana Forte Mazzeu; Ana Carolina Acevedo; Francisco de Assis Rocha Neves Journal: BMC Nephrol Date: 2015-07-02 Impact factor: 2.388
Authors: Félix Claverie-Martín; Víctor García-Nieto; Cesar Loris; Gema Ariceta; Inmaculada Nadal; Laura Espinosa; Ángeles Fernández-Maseda; Montserrat Antón-Gamero; Africa Avila; Álvaro Madrid; Hilaria González-Acosta; Elizabeth Córdoba-Lanus; Fernando Santos; Marta Gil-Calvo; Mar Espino; Elena García-Martinez; Ana Sanchez; Rafael Muley Journal: PLoS One Date: 2013-01-03 Impact factor: 3.240